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proved to be efficacious in the management of SSTI. An economic evaluation was
performed to determine the most cost-effective alternative between daptomycin
and linezolid for the treatment of SSTI with failure to vancomycin therapy.
METHODS: A cost-effectiveness analysis was performed from an institutional per-
spective (Mexican Institute of Social Security, IMSS). Both drugs are includedwithin
the treatment guidelines as secondary therapy for SSTI following vancomycin fail-
ure. As required per guidelines, use of concomitant therapy with ciprofloxacin and
metronidazole was also considered. Effectiveness and safety data was taken from
published literature; effectiveness parameters included clinical and microbiologi-
cal cure, and safety parameters includeddrug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built, considering two possible outcomes: success and failure to treatment. A prob-
abilistic sensitivity analysis was performed through aMonte Carlo simulationwith
100,000 iterations to confirm the robustness of the model. RESULTS: The results
show a cost/effectiveness ratio of $52,135.67 MXP for daptomycin compared to
$67,623.14 MXP for linezolid, making daptomycin a more cost-effective alternative
(dominant) for the treatment of SSTI. The sensitivity analysis confirmed the ro-
bustness of the model. CONCLUSIONS: From an institutional perspective in Mex-
ico, daptomycin is a more cost-effective (dominant) alternative than linezolid for
the treatment of SSTI in patients that failed treatment with vancomycin.
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OBJECTIVES: To evaluate the cost effectiveness analysis of Efavirenz/Emtricit-
abine/Tenofovir ((TDFFTCEFV) in naïve patientswithHIV from the public health
system Mexican perspective. METHODS: A decision tree model was developed to
estimate the efficacy and expected value of direct medical costs. Efficacy wasmea-
sured by the percentage of individuals with plasma HIV RNA  50 copies/mL and
and 400 copies/mL. at 96 weeks, based on a systematic review andmeta-analysis
of clinical trials of regimens in treatment-naïve populations. Model follows the
recommendations of antiretroviral persons handling Guide with HIV in Mexico
(2009 SSA). The direct costs and treatment of adverse events in the treatment of
HIV were estimated. When the patient failure, the cost of new treatment was
added. The unitary costs were obtained from the Mexican public health institu-
tions. All costs were calculated in 2010 Mexican Pesos (MXP). Incremental-cost-
effectiveness-ratios were expressed as cost per 1% of individuals with plasma HIV
RNA  50 copies/mL and and  400 copies/mL Costs and outcomes were dis-
counted at 5%. Probabilistic sensitivity analyses via Monte Carlo simulations were
undertaken to incorporate likely distributional properties of key model. RESULTS:
EFVFTCTDF was most effective than others comparators with probability of
0.734 (CI95%:0.601-0.835; n514) -except when compare with TDF/FTC  ATV/r
with efficacy of 0.743 CI95%:0.700-0.786; n440- and 0.746 (0.686-0.798; n232) of
having 50 or 400 RNA copies/ml respectively at 96 weeks, EFVFTCTDF re-
sulted as the alternative with less unitary average total cost ($60,026.00 MX and
$60,122.00, respectively). TDF/FTC/EFV combination is a dominant option and cost
saving compared to alternatives, except TDF/FTC  ATV/r (cost per 1% of individ-
uals with plasma HIV RNA  50 copies/mL of $8,490,581).Deterministic and prob-
abilistic sensitivity analysis showed that the findings are robust. CONCLUSIONS:
Efavirenz/Emtricitabine/Tenofovir is a cost effective drug on 96weeks for the treat-
ment of adult naïve patients with HIV infection in Mexico.
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OBJECTIVES: This study predicted and analyzed outcomes among six options (uni-
versal antiviral therapy without testing [Universal], empiric therapy without test-
ing [Empiric], empiric therapy with lab testing [Empiric_Lab], treatments respond-
ing to lab results [Standard], treatments responding to point-of-care testing [POCT]
results and no treatment [NoTx]) in healthy adults with influenza-like symptoms
who visit physicians within or beyond 48 hours of the onset of symptoms.
METHODS: A decision model was created to predict total and direct medical costs,
symptom-free days, quality of life and days of work lost within 14 days from the
perspective of patients. Most model inputs were derived from the literature; some
were obtained from internal data and expert opinions. Total costs (in $2009 USD)
included costs associated with prescriptions/OTC, tests, complications, hospital-
ization and work-day loss. Cost-effectiveness analysis, cost-utility analysis and
probabilistic sensitivity analysis were performed. RESULTS: Total costs per symp-
tom-free day were $119 ($874/7.3), $130 ($893/6.9), $163 ($1,086/6.7), $162 ($1,103/
6.8), $189 ($1,117/5.9) and $280 ($1117/4.2) for Universal, NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Total costs per quality of lifewere $1,560 ($874/
0.56), $1,641 ($893/0.54), $2,156 ($1,086/0.50), $1,949 ($1,103/0.57), $1,993 ($1,117/0.56)
and $2,195 ($1117/0.54) for Universal, NoTx, Standard, POCT, Emiric_Lab and Empiric,
respectively. Direct medical costs were $238, $169, $380, $336, $358 and $193 for Uni-
versal, NoTx, Standard, POCT, Emiric_Lab and Empiric, respectively. Direct medical
costs per symptom-free daywere $46, $25, $57, $49, $60 and $$46 for Universal, NoTx,
Standard, POCT, Emiric_LabandEmpiric, respectively.Directmedical costsperquality
of lifewere $425, $311, $755, $594, $639and$$360 forUniversal,NoTx, Standard, POCT,
Emiric_Lab and Empiric, respectively. Sensitivity analysis indicated the study results
were robust.CONCLUSIONS:With consideration of total costs, the universal option
was themost cost-effective option.With consideration of directmedical costs only,
no treatment is the most cost-effective option.
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OBJECTIVES:Antiretroviral combinations have been successful in delaying human
immunodeficiency virus (HIV) progression; however, drug resistance may occur.
Maraviroc and enfuvirtide are two drugs currently used in treatment-experienced
HIV patients. The objective was to determine the economic impact of maraviroc
versus enfuvirtide in HIV patients previously treated with conventional
antiretrovirals.METHODS:AMarkovmodelwas developed to assess the economic
consequences of the targeted therapies. The type of analysis was cost-minimiza-
tion based on the premise of clinical equivalence. The clinical outcome used to
support the clinical assumption was the odds ratio of decreasing1.0 log10 viral
copies/ml over placebo. Targeted populationwas composed of adults infectedwith
HIV virus (CCR5 co-receptor tropism), who underwent previous anti-HIV treat-
ments and proved therapeutic failure. Model input data derived from a previously
observed cohort of HIV patients in Brazil. A lifetime horizon was used. The eco-
nomic perspectivewas that of the BrazilianMinistry of Health (MoH) as a payer and
provider of medical services, treatments, and healthcare to its beneficiaries. Costs
were expressed in 2010 Brazilian Currency (1BRL0.59USD). Univariate and multi-
variate (Monte Carlo) analyses tested model robustness. RESULTS: An indirect
comparison between the interventions showed that the effects of the drugs over
placebo was similar from a clinical (odds ratios with approximate values) and
statistical (overlapping confidence intervals) standpoints. Thus, clinical equiva-
lence between the drugs was assumed. The economic analysis showed that the
total cost of anti-HIV treatment per patient with maraviroc was approximately
BRL17 thousand lower than enfuvirtide. Probabilistic sensitivity analysis reported
87% chance of having reduced treatment costs by choosing maraviroc over
enfuvirtide. CONCLUSIONS: The use of maraviroc in treatment-experienced HIV
patients showed to be beneficial for the Brazilian MoH in reducing the economic
burden of the disease. The estimated annual budget impact ranged between BRL
8.0 to 10.5 million favorable to cost reduction.
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OBJECTIVES:Raltegravir, an integrase inhibitor ofHIV-1, is approved for use in both
treatment naïve and treatment experienced HIV-1 infected patients. In Sweden,
raltegravir is reimbursed for patients with documented drug resistance and used
predominately in heavily treated experienced patients. This study aims to inves-
tigate the cost-effectiveness of using raltegravir in treatment naïve patients versus
using raltegravir as a salvage treatment.METHODS:A three-stage continuous-time
Markovmodel representing successive HIV therapies was developed to predict the
costs and quality-adjusted life years (QALYs) over a 50-year time horizon. Patients
progressed to the next stage in themodel as they failed or discontinued the current
therapy for toxicity reasons. In each stage patientsmoved between 18 health states
based on CD4 and HIV RNA levels. At anytime patients could die, suffer coronary
heart disease or develop acquired immunodeficiency syndrome (AIDS). Initiation
on a raltegravir-based regimen was evaluated versus initiation on a protease in-
hibitor (PI)-based regimen. During the second stage patients received a non-nucle-
oside reverse transcriptase inhibitor based regimen. Patients initiating on raltegra-
vir progressing to the third stage received optimized salvage therapy (OT) whereas
patients initiating on a PI received OT plus raltegravir. Data on effectiveness was
gathered from randomized clinical trials and an HIV/AIDS database. Utilities and
health care resource usewere gathered from the literature and adapted to Swedish
situation using expert opinion. RESULTS: Raltegravir-initiating treatment strategy
offered longer undiscounted life expectancy compared to PI initiating strategy
[20.51 vs. 18.60 years]. The incremental cost-utility ratio for using raltegravir in
treatment naïve patients versus using raltegravir as a salvage treatmentwas 85 182
SEK per QALY ($12,564/QALY). Results were sensitive to analytical time horizon.
CONCLUSIONS: Given the data and methods used, the model suggests that using
raltegravir in treatment naïve patients compared to using raltegravir as a salvage
therapy is cost-effective.
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OBJECTIVES: Although influenza affects all age groups, influenza is common in
children. Between 15% and 42% of preschool and school-aged children experience
influenza each season. Recently, LAIV has been approved in Canada for use in
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